Corcept Therapeutics Incorporated (CORT) Company Bio
Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders. The company was founded in 1998 and is based in Menlo Park, California.
CORT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Corcept Therapeutics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Corcept Therapeutics Inc ranked in the 95th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for CORT, they are:
The stock's equity weight, or the proportion of capital from equity relative to debt, is 100. Its equity weight surpasses that of 93.96% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 2.41% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
Corcept Therapeutics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -23.96. This coverage rate is greater than that of only 4.96% of stocks we're observing for the purpose of forecasting via discounted cash flows.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
THC, RDY, DVCR, FVE, and INBP can be thought of as valuation peers to CORT, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Corcept Therapeutics ([[CORT]] +1.2%) enrolls first patient in RELIANT, a Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s Abraxane) in patients with metastatic pancreatic cancer.The company plans to enroll 80 patients, with an interim analysis of data from the first 40 patients.The primary endpoint is objective response rate, with...
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of the first patient in RELIANT, an open-label, Phase 3 trial of relacorilant in combination with nab-paclitaxel (Celgene’s medication, Abraxane®) in patients with metastatic pancreatic cancer. “Metastatic pancreatic cancer is an aggressive disease and there is an urgent need for effective therapies,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. RELIANT has a planned enrollment of 80 patients with metastatic pancreatic cancer, with an interim analysis of data from the first 40 patients.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]